Dima Shulkin: A Novel Monocyte-Based Biomarker of Cardiovascular Risk
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn:
“What if a simple blood test could flag hidden heart disease long before any symptoms appear?
A 2024 medRxiv preprint by Almarri and colleagues (not yet peer-reviewed) explored exactly that.
They studied symptom-free adults, first a small group of 39, then 151 more in Nanjing, China, measuring immune cells called monocytes (part of the body’s defense team) and how often they clump with platelets.
The readings became a new score, MARS, which tracked real artery damage far more closely than the standard risk calculators doctors use now.
Early research, but a real hint that a blood sample may reveal what checklists miss.”
Other posts featuring Dima Shulkin on Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough